Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) / F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C.H. Barrios, J. Bergh, L. Biganzoli, C.B. Boers-Doets, M.J. Cardoso, L.A. Carey, J. Cortés, G. Curigliano, V. Dié Ras, N.S. El Saghir, A. Eniu, L. Fallowfield, P.A. Francis, K. Gelmon, S.R.D. Johnston, B. Kaufman, S. Koppikar, I.E. Krop, M. Mayer, G. Nakigudde, B.V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H.S. Rugo, G.W. Sledge, D. Spence, C. Thomssen, D.A. Vorobiof, B. Xu, L. Norton, E.P. Winer. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:8(2018 Aug), pp. 1634-1657. [10.1093/annonc/mdy192]
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
G. Curigliano;
2018
Abstract
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5-year survival of only 25% [2, 3]. The MBC Decade Report [2] shows that progress has been slow in terms of improved outcomes, quality of life (QoL), awareness and information regarding ABC. More recently, some studies seem to indicate an improvement in OS, mostly due to advances in human epidermal growth factor receptor 2 (HER2)-positive ABC [4-6]. The better survival is seen in an environment with access to the best available care and particularly in de novo ABC, while recurrent ABC seems to become harder to manage [7, 8].
| File | Dimensione | Formato | |
|---|---|---|---|
|
ABC4.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
347.96 kB
Formato
Adobe PDF
|
347.96 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
